2024
MISTRG6kitW41: Enhanced Engraftment in a Cytokine Humanized Patient-Derived Xenotransplantation Mouse Model
Baassiri A, Maziarz J, Blackburn H, Maul-Newby H, VanOudenhove J, Zhang X, Matthews M, Paul S, Liu W, Sefik E, Salomonis N, Grimes H, Flavell R, Halene S. MISTRG6kitW41: Enhanced Engraftment in a Cytokine Humanized Patient-Derived Xenotransplantation Mouse Model. Blood 2024, 144: 1815-1815. DOI: 10.1182/blood-2024-211908.Peer-Reviewed Original ResearchPeripheral blood-mobilized stem cellsAcute myeloid leukemiaProgression to secondary acute myeloid leukemiaHematopoietic stem cellsWeeks post-engraftmentSecondary acute myeloid leukemiaStudies of myelodysplastic syndromesMyelodysplastic syndromeCD34+ cellsEngraftment levelsPeripheral bloodBone marrowK micePost-engraftmentMouse modelNSG miceMDS samplesEngraftment of human hematopoietic stem cellsEnhanced engraftmentProgression to acute myeloid leukemiaHealthy donor peripheral bloodHuman CD45+ cellsHuman hematopoietic stem cellsAnalysis of CD34+ cellsPercentage of lymphoid cells
2014
ΜΙSΤRG Mice Support Good-Risk AML Engraftment
Ellegast J, Saito Y, Flavell R, Manz M. ΜΙSΤRG Mice Support Good-Risk AML Engraftment. Blood 2014, 124: 3808. DOI: 10.1182/blood.v124.21.3808.3808.Peer-Reviewed Original ResearchGood-risk acute myeloid leukemiaRisk acute myeloid leukemiaAcute myeloid leukemiaAML engraftmentMISTRG miceEngraftment levelsNSG miceTherapeutic strategiesAML samplesGM-CSFAggressive acute myeloid leukemiaM-CSFHuman AML samplesBone marrow aspirationPeripheral blood analysisAggressiveness of diseaseBone marrow analysisGenetic alterationsExtent of engraftmentUnsatisfactory treatment optionsNovel therapeutic strategiesDirect therapeutic strategiesPreliminary data pointAML presentationCD19 depletion
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply